

Contact: Doug Guarino
Jon Russell

Director of Corporate Relations
Vice President of Finance

781-647-3900

**ALERE INC. ANNOUNCES
FOURTH QUARTER 2013 RESULTS**

WALTHAM, MA...February 6, 2014...Alere Inc. (NYSE: **ALR**), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today announced its financial results for the quarter ended December 31, 2013.

Ron Zwanziger, Chairman, Chief Executive Officer and President of Alere said, “Our strong fourth quarter results complete a very successful year for Alere. Our focus on organic growth, expense control and value creation for our shareholders positions us well for continued improvements in 2014 and beyond.”

Financial results for the fourth quarter of 2013:

- Net revenue of \$772.3 million for the fourth quarter of 2013, compared to \$755.8 million for the fourth quarter of 2012. Non-GAAP adjusted net revenue was \$772.8million for the fourth quarter of 2013, compared to \$756.5 million for the fourth quarter of 2012.
- Net loss of \$9.1 million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of \$0.11, for the fourth quarter of 2013, compared to net loss of \$68.0 million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of \$0.84, for the fourth quarter of 2012.
- Non-GAAP adjusted net income per diluted common share of \$0.68 for the fourth quarter of 2013, compared to non-GAAP adjusted net income per diluted common share of \$0.55 for the fourth quarter of 2012.
- Net product and services revenue from our Professional Diagnostics segment was \$600.7 million in the fourth quarter of 2013, compared to net product and services revenue of \$584.1 million in the fourth quarter of 2012. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment was \$601.1 million in the fourth quarter of 2013, compared to non-GAAP adjusted net product and services revenue of \$584.9 million in the fourth quarter of 2012. Recent professional diagnostics acquisitions contributed \$27.2 million of incremental net revenue compared to the fourth quarter of 2012, offset by a reduction in revenue of \$6.3 million related to dispositions in the quarter.
- North American influenza sales decreased to \$20.9 million for the fourth quarter of 2013, from \$23.0 million for the fourth quarter of 2012.
- Excluding the impact of the change in North American influenza revenues and the impact on

revenues from the reduction in our U.S. meter-based Triage product sales, currency adjusted organic growth in our Professional Diagnostics segment was 2.0%. This growth rate was adversely impacted by the change in reimbursement rates which became effective on July 1, 2013 for our U.S. mail order diabetes business. Excluding revenues from our U.S. mail order diabetes business and considering the flu and Triage adjustments, the currency adjusted organic growth rate for the quarter was 5.2% for the remainder of our Professional Diagnostics segment.

- Net product and services revenue from our Health Information Solutions segment was \$130.0 million in the fourth quarter of 2013, compared to \$131.0 million in the fourth quarter of 2012 and \$134.2 million in the third quarter of 2013.
- Included in royalty revenues in the fourth quarter of 2013 was \$8.5 million associated with the license of certain of our molecular intellectual property, compared with \$11.0 million during the fourth quarter of 2012.
- Included in interest and other income (expense), is an incremental provision of \$4.5 million to reflect an estimate of the settlement or litigation costs, which we may incur associated with an ongoing dispute with a customer in our U.S. toxicology business during the fourth quarter of 2013, and a charge of a \$3.9 million associated with the settlement of a prior year dispute with a former distributor during the fourth quarter of 2012.

The Company's GAAP results for the fourth quarter of 2013 exclude \$0.5 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of \$81.4 million, \$7.8 million of restructuring charges, \$6.7 million of stock-based compensation expense, \$1.3 million of acquisition-related costs recorded in accordance with ASC 805, *Business Combinations*, \$6.1 million of costs associated with potential business dispositions, \$0.4 million of interest expense recorded in connection with fees paid for certain debt modifications, \$0.8 million in compensation charges and \$0.1 million of related interest accretion associated with acquisition-related contingent consideration obligations, a \$0.6 million charge associated with the write-up to fair market value of inventory acquired in connection with the acquisition of Epocal Inc., \$0.1 million of costs associated with the proxy contest, offset by an \$0.8 million reduction in the loss on disposition of our Spinreact, S.A. subsidiary located in Spain, and \$1.0 million of income recorded for fair value adjustments to acquisition-related contingent consideration. The Company's GAAP results for the fourth quarter of 2012 exclude \$0.8 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of \$105.1 million, \$10.3 million of restructuring charges, \$3.8 million of stock-based compensation expense, \$3.6 million of acquisition-related costs recorded in accordance with ASC 805, *Business Combinations*, \$10.2 million of expense recorded for fair value adjustments to acquisition-related contingent consideration, \$1.0 million of interest expense recorded in connection with fees paid for certain debt modifications, and \$23.2 million of expense associated with the extinguishment of debt.

These amounts, net of tax, have been excluded from the non-GAAP adjusted net income per diluted common share attributable to Alere Inc. for the respective quarters.

Detailed reconciliations of the non-GAAP financial measures presented in this release to the most directly comparable financial measures under GAAP, as well as a discussion regarding these non-GAAP financial measures, are included in the schedules to this press release.

The Company will host a conference call beginning at 8:30 a.m. (Eastern Time) today, February 6, 2014, to discuss these results, as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.

The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international) and asking for Alere Inc. A webcast of the call can also be accessed via the Alere website at <http://www.alere.com/us/en/about/investor-relations/events.html>, or directly through the following link: <http://www.videonewswire.com/event.asp?id=97913>.

A replay of the call will be available approximately one hour after the conclusion of the call and will remain available for a period of seven days following the call. The replay may be accessed by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and entering replay code 10040461. The replay will also be available via online webcast at <http://www.videonewswire.com/event.asp?id=97913> or via the Alere website at <http://www.alere.com/us/en/about/investor-relations/events.html> for a period of 60 days following the call.

Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the Alere website (<http://www.alere.com/us/en/about/investor-relations/events.html>) under the Earnings Calls and Releases section shortly before the conference call begins and will continue to be available on this website.

For more information about Alere, please visit our web site at <http://www.alere.com>.

By developing new capabilities in near-patient diagnosis, monitoring and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology and diabetes. Alere is headquartered in Waltham, Massachusetts.

Source: Alere Inc.